AstraZeneca has completed an exclusive global license agreement with KYM Biosciences Inc. for CMG901, a potential first-in-class antibody drug conjugate (ADC) targeting Claudin 18.2, a promising therapeutic target in gastric cancers.
CMG901 is currently being evaluated in a Phase I trial for the treatment of Claudin 18.2-positive solid tumors, including gastric cancer. Preliminary results from the trial have shown an encouraging profile for CMG901, with early signs of anti-tumor activity across the dose levels tested.
Financial considerations
AstraZeneca has entered into an exclusive global license for the research, development, manufacture and commercialization of CMG901 for an upfront payment of $63m, with potential development and sales-related milestone payments of up to $1.1bn and tiered royalties up to low double digits.
The transaction does not impact AstraZeneca’s financial guidance for 2023.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!